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CDKL5 variants
Improving our understanding of a rare neurologic disorder
ABSTRACT
Objective: To provide new insights into the interpretation of genetic variants in a rare neurologic
disorder, CDKL5 deficiency, in the contexts of population sequencing data and an updated
characterization of the CDKL5 gene.
Methods: We analyzed all known potentially pathogenic CDKL5 variants by combining data from
large-scale population sequencing studies withCDKL5 variants from new and all available clinical
cohorts and combined this with computational methods to predict pathogenicity.
Results: The study has identified several variants that can be reclassified as benign or likely
benign. With the addition of novel CDKL5 variants, we confirm that pathogenic missense variants
cluster in the catalytic domain of CDKL5 and reclassify a purported missense variant as having
a splicing consequence. We provide further evidence that missense variants in the final 3 exons
are likely to be benign and not important to disease pathology. We also describe benign splicing
and nonsense variants within these exons, suggesting that isoform hCDKL5_5 is likely to have
little or no neurologic significance. We also use the available data to make a preliminary estimate
of minimum incidence of CDKL5 deficiency.
Conclusions: These findings have implications for genetic diagnosis, providing evidence for the
reclassification of specific variants previously thought to result in CDKL5 deficiency. Together,
these analyses support the view that the predominant brain isoform in humans (hCDKL5_1) is
crucial for normal neurodevelopment and that the catalytic domain is the primary functional
domain. Neurol Genet 2017;3:e200; doi: 10.1212/NXG.0000000000000200
GLOSSARY
dbSNP 5 Single Nucleotide Polymorphism database; ExAC 5 Exome Aggregation Consortium; NMD 5 nonsense-mediated
decay; RettBASE5 Rett Syndrome Database; RT5 reverse transcription; UTR5 untranslated region; VEP5 Variant Effect
Predictor; XCI 5 X-chromosome inactivation; 1000G 5 1000 Genomes Project.
The phenotype associated with CDKL5 deficiency (MIM: 300203) has become increasingly well
defined over the last decade. Its cardinal features are early-onset seizures, often presenting as infan-
tile spasms and usually occurring within the first 3 months of life, global developmental delay, and
severely impaired gross motor function.1 CDKL5 deficiency is caused by dominantly acting loss-of-
function variants in the X-linked gene CDKL5 (cyclin-dependent kinase-like 5), which plays
a crucial role in brain development.2–6 The epidemiology of CDKL5 deficiency has not been
studied, and no incidence or prevalence data are available. Nevertheless, the frequency of patients
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diagnosed with CDKL5 deficiency is increasing
due to growing awareness of the disorder and
the inclusion of CDKL5 in routine genetic test-
ing of early-onset epileptic encephalopathies.7,8
For rare Mendelian diseases caused by de
novo variants, such as CDKL5 deficiency, data
from large-scale screening of patient and pop-
ulation samples can be mined to enhance clar-
ification of clinically relevant variants. The
Exome Aggregation Consortium (ExAC)9 ana-
lyzed high-quality exome DNA sequence data
of 60,706 individuals of diverse ancestries,
providing opportunities to refine the clinical
interpretation of CDKL5 variants. Here, we
analyze all known variants observed in
CDKL5 patients to date, including novel var-
iants described in this study, along with data
from ExAC, the 1000 Genomes Project
(1000G),10 and the Single Nucleotide Poly-
morphism database (dbSNP).11 All variants
are analyzed in the context of the updated
characterization of the CDKL5 gene12 to pro-
vide new insights into the clinical interpreta-
tion of variants in CDKL5 deficiency.
METHODS Standard protocol approvals, registrations,
and patient consents. Written informed consent was obtained
from all individuals who participated in this study, and the study
was approved by the ethics committees of the respective institu-
tions: University of Western Australia Human Research Ethics
Committee (reference # RA/4/1/5024); the Institute of Medical
Genetics, University Hospital of Wales (Cardiff, UK) as part of
the British Isles Rett Syndrome Survey (REC reference # 15/WA/
029); Children’s Hospital Colorado (Aurora, CO) (COMIRB
13-2020); established protocols to access clinical data of Sant
Joan de Déu Children’s Hospital (Barcelona, Spain).
CDKL5 variant data collection. CDKL5 variants in clinical
cohorts (see above) were analyzed by combining data from
the CDKL5 variation database at Rett Syndrome Database
(RettBASE),13 Database of Chromosomal Imbalance and Pheno-
type in Humans Using Ensembl Resources,14 and all published
reports of CDKL5 variants. Population data on CDKL5 variants
were sourced from ExAC,9 1000G,10 and dbSNP.11
Computational analysis. The effects of missense and splicing
variants in CDKL5 were predicted using several algorithms
(missense: SIFT, PolyPhen, MutationTaster, and PROVEAN;
splicing variants: MaxEntScan and dbscSNV), provided within
the Ensembl Variant Effect Predictor (VEP).15
Assignment criteria. The assignment of pathogenicity was
based on guidelines for the interpretation of sequence variants.16
The following criteria were used: pathogenic—the same amino
acid change as an established pathogenic variant; likely patho-
genic—the allele is absent in population data sets and the pa-
tient’s phenotype is highly specific for CDKL5 disorder, and
computational evidence supports a deleterious effect on the gene;
uncertain significance—evidence for benign and pathogenic clas-
sification is contradictory; likely benign—the variant is detected
in a healthy mother and/or sister, and computational evidence
suggests no effect on the gene; and benign—the variant is de-
tected in a healthy father and/or brother, or the allele frequency is
detected in population data sets at levels too high to explain the
prevalence of a rare disorder.
Minigene splicing assay. DNA fragments of wild-type and
mutant CDKL5 exon 14 with flanking intron sequence were
synthesized (IDT, Coralville, IA) and cloned into the exon trap
vector pET01 (MoBiTec, Göttingen, Germany). Minigenes were
transfected into HEK293T cells using jetPRIME (PEQLAB,
Erlangen, Germany) according to the manufacturer’s in-
structions. After 24 hours, total RNA was extracted using the
RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). Total RNA
was generated, and reverse transcription PCR (RT-PCR) ex-
periments were performed as described previously.17 Further
details of these experiments are described in e-Methods.
RESULTS CDKL5 variants in the population. The
number of expected and observed variants in CDKL5
from the recent large-scale analysis of genetic varia-
tion by ExAC is described in table 1.9 Synonymous
variants in CDKL5 are reported to occur at approxi-
mately the expected frequency and are found
throughout the coding region of CDKL5 (figure 1).
By contrast, the number of missense variants
observed (n 5 157) is lower than expected (table 1).
The population sample analyzed in the ExAC study
was devoid of severe pediatric disease; therefore, none
of these 157 missense variants is, on its own, patho-
genic and causative for CDKL5 deficiency. Only 15
(;10%) of these missense variants are located in the
catalytic domain of CDKL5, a 286-amino acid region
(;30% of protein length) crucial for protein func-
tion2 (figures 1 and 2). No frameshift or splicing
variants were identified in ExAC; however, 2 non-
sense variants (described as stop-gain in table 1) were
identified: p.Arg952Ter and p.Arg970Ter. Both
nonsense variants are found in exon 21 and therefore
affect only the hCDKL5_5 isoform, which is ex-
pressed almost exclusively in the testis.12,18
Some known exonic coding and untranslated re-
gions (UTRs) of CDKL5, recently identified and
present only in minor transcript isoforms,12 are not
included in the exonic regions covered by ExAC. For
example, exon 17 (originally termed 16b19) is present
Table 1 Expected and observed CDKL5 variants in ExAC
Variant type Expected no. of variants Observed no. of variants Constraint metric
Synonymous 99.4 111 Z 5 20.72
Missense 237.7 157 Z 5 2.56
Stop-gain 26.4 2 pLI 5 1.00
Abbreviation: ExAC 5 Exome Aggregation Consortium.
The expected number of variants was calculated using a gene-size and sequencing depth-
adjusted variant probability. The positive Z score for missense variants in CDKL5 indicates
increased intolerance to variation. The calculated pLI value of 1 indicates that CDKL5 is
extremely intolerant to loss-of-function variants (here referred to as “stop-gain”).
2 Neurology: Genetics
in the hCDKL5_2 isoform and is expressed only at
low levels in the developing and adult brain.12 Only 2
exon 17 variants have been identified, both in dbSNP
(rs289269000 and rs181987256), neither of which is
associated with a disease phenotype.
CDKL5 missense variants in patients. Missense variants
reported in patients are found throughout the portions
of CDKL5 that encode the major brain transcript
isoform, hCDKL5_1 (figure 1). Only 1 of the 15 mis-
sense variants identified within the catalytic domain in
ExAC has been reported in a patient with CDKL5
deficiency: c.719G.C (p.Ser240Thr; figure 2). This
exon 9 variant has recently been reported as the
first familial case of CDKL5-related disease20 in a het-
erozygous female, who displayed global psychomotor
delay and autistic disturbances but no epilepsy. The
same variant was detected in her asymptomatic
Figure 1 Distribution of exonic CDKL5 variants
A cartoon of the gene structure is given at the top, with exons of hCDKL5_1, the dominant brain transcript isoform, colored blue-green (coding regions) and
black (UTRs). Introns are not drawn to scale. In the diagram beneath, variant types are grouped together, and individual variants are plotted according to their
location in the gene. Red indicates pathogenic or likely pathogenic variants; green indicates benign or likely benign variants; and amber indicates variants of
uncertain significance.
Figure 2 Pathogenic CDKL5 missense variants cluster in the catalytic domain
Functional domains in the CDKL5 protein are color coded. Numbers refer to the positions of amino acids. Variants in red (upper) are pathogenic or likely
pathogenic. Variants in black (lower) are benign or likely benign. aVariant with a splicing consequence. bVariant of uncertain significance. NES 5 putative
nuclear export signal; NLS 5 putative nuclear localization signal; ST 5 serine-threonine kinase active site; TEY 5 conserved Thr-Glu-Tyr motif.
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mother, and a skewed X-chromosome inactivation
(XCI) ratio was thought to account for this phenotypic
difference. We further identified 2 individuals with
this variant (1 in ExAC and 1 in 1000G), neither
individual having displayed signs of a neuro-
developmental disorder phenotype, consistent with the
inclusion criteria in those studies. It is unlikely that 3
asymptomatic carriers of this variant would all have
similarly skewed XCI, suggesting that this variant may
not in fact be causative. Current evidence suggests that
the p.Ser240Thr should be classified as being of
“uncertain significance.”
Table 2 Novel CDKL5 variants in our clinical cohorts
Mutation
type Exon Gene variant GRCh38 ExAC AF
1000G
MAF dbSNP
Protein
consequence Sex
CDKL5 clinical
diagnosis
Computational
prediction
Missense 2 c.37T.C 18507133 — — — p.Phe13Ser Female Yes Pathogenic
Missense 3 c.71A.G 18510826 — — — p.Tyr24Cys Female Yes Pathogenic
Missense 4 c.104C.T 18564481 — — — p.Thr35Ile Female Yes Pathogenic
Missense 5 c.200T.C 18575408 — — — p.Leu67Pro Female Yes Pathogenic
Missense 6 c.364G.A 18579929 — — — p.Ala122Thr Female Yes Uncertain significance
Missense 6 c.377G.A 18579942 — — — p.Cys126Tyr Female Yes Uncertain significance
Missense 7 c.454T.C 18581941 — — — p.Cys152Arg Female Yes Pathogenic
Missense 9 c.605G.A 18588004 — — — p.Gly202Glu Female Yes Pathogenic
Missense 10 c.784T.C 18595387 — — — p.Tyr262His Female Yes Uncertain significance
Missense 11 c.853A.G 18598489 — — — p.Arg285Gly Female Yes Pathogenic
Missense 11 c.950A.Ga 18598586 2.28E-05 — rs756537286 p.His317Arg Male — Uncertain significance
Missense 12 c.1188T.Aa 18604112 1.14E-05 — rs772076629 p.Asp396Glu Female — Uncertain significance
Missense 15 c.2243A.Ga 18613242 6.84E-05 0.0003 rs748459878 p.Asn748Ser Female — Benign
Missense 20 c.2716G.A 18646009 2.28E-05 — rs369009993 p.Gly906Ser Female — Benign
Missense 21 c.2980G.Aa 18650592 — — — p.Gly994Arg Female — Benign
Nonsense 5 c.205C.T 18575413 — — — p.Gln69Ter Female Yes —
Nonsense 5 c.258C.G 18575466 — — — p.Tyr86Ter Female Yes —
Nonsense 11 c.858C.A 18598494 — — — p.Tyr286Ter Female Yes —
Nonsense 14 c.2112C.G 18609530 — — — p.Tyr704Ter Female Yes —
Nonsense 15 c.2276G.A 18613275 — — — p.Trp759Ter Female Yes —
Nonsense 21 c.2941C.T 18650553 — — — p.Arg981Ter Female Yesb —
Splicing IVS2 c.65-2A.T 18510818 — — — — Female Yes Pathogenic
Splicing IVS2 c.65-2A.G 18510818 — — — — Female Yes Pathogenic
Splicing IVS6 c.404-1G.C 18581890 — — — — Female Yes Pathogenic
Splicing IVS10 c.82511G.A 18595429 — — — — Female Yes Pathogenic
Splicing IVS10 c.82511G.A 18595429 — — — — Female Yes Pathogenic
Splicing IVS10 c.826-1G.A 18598461 — — — — Female Yes Pathogenic
Splicing IVS15 c.227611G.T 18613276 — — — — Female Yes Pathogenic
Splicing IVS20 c.279712T.C 18664209 — — — — Male — Pathogenic
Triplication 1–15 X:18370935-
18634410 x3
— — — — — Female — —
Duplication 3–12 X:18510568-
18605032 x2
— — — — — Female — —
Duplication IVS1 X:18488669-
18516147 x2
— — — — — Female — —
Abbreviations: dbSNP 5 Single Nucleotide Polymorphism database; ExAC 5 Exome Aggregation Consortium; VEP 5 Variant Effect Predictor; 1000G 5
1000 Genomes Project.
Variants are grouped into types. GRCh38 indicates the X-chromosome coordinate in the GRCh38/hg38 assembly.
a Variant inherited from an asymptomatic mother.
Frequencies of variants in population databases are shown as ExAC allele frequency (AF) and 1000G minor allele frequency (MAF). CDKL5 clinical
diagnosis was made by the clinical center to which the patient presented (bmilder-than-average CDKL5 symptoms). Computational prediction is based on
analysis using the Ensembl VEP.
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Combining all known CDKL5 variant data, there
are 59 missense variants in the catalytic domain, which
we consider pathogenic or likely pathogenic for CDKL5
deficiency based on our assignment criteria (figure 2).
This includes 11 novel missense variants identified in
the clinical cohorts in this study (table 2). In each case,
the patient received a clinical diagnosis of CDKL5 defi-
ciency, and, in most cases, VEP analysis supported the
prediction of a pathogenic variant.
Outside the catalytic domain, there are 179 differ-
ent missense variants (figure 1). Upstream of the cat-
alytic domain, 3 variants (p.Ile3Phe, p.Asn5Asp, and
p.Ile6Thr) are known to be present in ExAC
and 1000G, not associated with CDKL5 patients
and predicted to be benign by VEP analysis. Fifty-
one different missense variants have been found in the
last 3 exons (20, 21, and 22). Forty of these are
present in ExAC, often in hemizygous males.
c.2995G.A (p.Val999Met), previously thought to
be pathogenic, is found at notable frequency in ExAC
(0.01178) and should therefore be classed as a benign
polymorphism. A further 10 are present in dbSNP;
none of these variants appear to be responsible for
a CDKL5-like phenotype, and VEP analysis predicts
these variants to be benign. This is consistent with
these exons being absent in the primary brain tran-
script isoform. In our clinical cohorts, a variant in
exon 21, c.2980G.A (p.Gly994Arg), was identified
in a patient with developmental delay, but was not
clinically diagnosed with CDKL5 deficiency (table 2).
The variant was inherited from her asymptomatic
mother and, combined with VEP analysis, should
therefore be classified as benign.
The remaining missense variants are distributed
between exons 11 and 19 (figure 1). Ninety-seven
of these are found in ExAC, many occurring in
hemizygotes. In some cases, such as p.Ile508Thr
and p.Thr734Ala, the ExAC allele frequency and
the presence of these variants in hemizygotes allow
them to be reclassified as likely benign. Additional
variants present in dbSNP (but not in ExAC) are
not associated with any clinical phenotype. In our
clinical cohorts, we identified further missense var-
iants in patients, where a clinical diagnosis of CDKL5
deficiency was not given (table 2). p.His317Arg,
p.Asp396Glu, p.Asn748Ser, and p.Asp797Asn are
present in ExAC/1000G, and all variants were iden-
tified as being inherited from a healthy mother or
father (table 2), suggesting that they are all benign
variants. In our analysis, there are 7 missense variants
outside the catalytic domain that should, at present,
be classified as “of uncertain significance” pending
more information (figure 2). p.Val351Ile is recorded
in dbSNP (rs587783150) and p.Thr538Ala is re-
corded in the RettBASE,13 for which no clinical or
screening information is available. p.Leu302Phe and
p.Asp422Glu are unique variants that have been asso-
ciated with seizure phenotypes, although the pheno-
type of these cases is atypical in comparison to other
CDKL5 patients reported in these studies.21,22 p.
Asn399Thr and p.Val793Ala have also been associ-
ated with epilepsy phenotypes4,23; these variants have
also been observed as singletons in ExAC.
The most compelling evidence of a pathogenic
missense variant outside the catalytic domain con-
cerns the c.2152G.A (p.Val718Met) variant. This
variant has been identified in 3 unrelated CDKL5
patients in 3 independent studies.24–26 In each case,
the patient presented with symptoms consistent with
CDKL5 deficiency and harbored no known variants
in other epilepsy-related genes. This variant is not
present in the 1000G or the ExAC population
Figure 3 CDKL5 variant c.2152G>A causes skipping of exon 14 in HEK293T cells
(A) Schematic representation of the minigene constructs used in the in vitro splicing assay (not to scale). The pET01 vector
contains 59 and 39 exons separated by an intron sequence. Minigenes contain wild-type (wt) or mutant (mut; c.2152G.A)
CDKL5 exon 14 sequences flanked by portions of their natural introns (thick lines). Primers used for RT-PCR experiments
are indicated by arrows. Splicing events, indicated by dashed lines, would result in a 348-bp or a 242-bp product depending
on inclusion or otherwise of CDKL5 exon 14. (B) Agarose gel showing RT-PCR results from the splicing assay using pET01
vector and minigenes of wild-type or mutated CDKL5 exon 14. Upper bands (348 bp) indicate the presence of exon 14,
whereas lower bands (242 bp) indicate exclusion of exon 14. Marker indicates 100 bp ladder; 2RT indicates a negative
control without reverse transcriptase.
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databases. VEP analysis of c.2152G.A, which affects
the last base of exon 14, predicted a detrimental effect
on splicing (MaxEntScan diff: 2.89). We assessed this
variant in vitro using a minigene splicing assay, show-
ing that splicing is disrupted, resulting in exon 14
being omitted from the transcript (figure 3). We
therefore suggest that the c.2152G.A variant be cat-
egorized as a splicing rather than a missense variant.
The consequence (r.2047_2152del) is a frameshift
variant that would generate a premature stop codon
in exon 16. This finding removes evidence supporting
the existence of pathogenic missense variants outside
the catalytic domain of CDKL5, and we therefore
conclude that caution should be applied in interpre-
tations of pathogenicity whenever an apparent mis-
sense variant is found outside the catalytic domain.
Nonsense, frameshift, and splicing variants. Pathogenic
nonsense, frameshift, and splicing variants are found
throughout the coding region of hCDKL5_1, the pre-
dominant brain transcript isoform (figure 1). Efforts
have been made to establish genotype-phenotype re-
lationships based on the position of these variants in
the gene, by predicting structural and functional
consequences.8 However, the levels of functional
CDKL5 in patients with truncating variants at dif-
ferent points throughout the gene are still not known.
Novel nonsense and splicing variants identified in the
clinical cohorts in this study are described in table 2,
and novel frameshift variants in table e-1, http://links.
lww.com/NXG/A2.
In exon 19, the last exon utilized by the
hCDKL5_1 transcript, a variant described in dbSNP
(rs863225289) has been identified in a patient with
early infantile epileptic encephalopathy 2 (MIM:
300672). This variant lies downstream of the internal
splice donor site in exon 19 and so would not be ex-
pected to affect the protein product made from the
testis-specific hCDKL5_5 transcript isoform. However,
in relation to hCDKL5_1, the major brain transcript
isoform, this is a nonsense variant (c.2176C.T,
p.Gln906Ter, with respect to hCDKL5_1). This may
trigger nonsense-mediated decay (NMD; due to the
presence of a long 39-UTR27) and result in typical
CDKL5 deficiency. Additional observations of this var-
iant would be required to validate this conjecture, but it
is consistent with the idea that truncating variants in
exon 19 may be pathogenic.
Three nonsense variants have been detected in
exon 21, which is specific to isoform hCDKL5_5:
c.2854C.T, p.Arg952Ter; c.2908C.T, p.
Arg970Ter; and c.2941C.T, p.Arg981Ter. Both
p.Arg952Ter and p.Arg970Ter variants have
been described in patients with CDKL5-like symp-
toms.28,29 However, in both cases, delay in seizure
onset and an absence of other features of CDKL5-
associated pathology were reported. p.Arg952Ter was
identified in the patient’s mother, grandmother,
and half-sister, and in 6 individuals in a control pop-
ulation.28 A further 12 instances of this allele are
present in ExAC, including 3 hemizygotes (allele fre-
quency 0.0001367). A recent case study also identi-
fied this variant in an asymptomatic hemizygous
male.30 p.Arg970Ter occurs in a single heterozygous
female in ExAC (in the case study, the variant was not
detected in the mother and the father was deceased29).
Together, these findings suggest that variants in these
late exons do not cause a CDKL5 deficiency
phenotype.
A c.2941C.T, p.Arg981Ter variant was identi-
fied in our clinical cohorts (table 2). A girl presented
with a phenotype consistent with CDKL5 deficiency
—profound cognitive impairment, mild dysmorphic
appearance, stereotypical hand wringing, and epilepsy
(from age 6 months). Both parents were deceased;
therefore, it is unknown whether this variant was in-
herited or occurred de novo. This variant is not pres-
ent in ExAC or in 1000G, and the clinical evidence
would suggest defining this as a pathogenic variant.
However, this variant lies immediately downstream of
the 2 nonsense variants described above, both of
which have considerable evidence suggesting that
they should be classified as benign. We conclude that,
at present, p.Arg981Ter should be classified as being
of “uncertain significance.”
It is important that no pathogenic frameshift or
splicing variants were found affecting exons 20, 21,
and 22 (figure 1). A novel splicing variant was
identified in our clinical cohorts (table 2):
c.279712T.C. The patient, a boy, was not clini-
cally diagnosed with CDKL5 deficiency and was
found to have inherited the variant from his asymp-
tomatic mother. VEP analysis of this variant predicts
the abolition of the splice donor site of exon 20,
which would be likely to result in a premature stop
codon.
Copy number variations and CDKL5 duplication. Sev-
eral studies have reported duplications of Xp22 asso-
ciated with intellectual disability and autism
phenotypes,31–34 but the duplicated regions reported
(spanning 8–21 Mb) included as many as 80 genes,
and interpretation of gene-specific overexpression
effects in such circumstances is problematic. A more
recent study described 3 unrelated families with more
compact duplication regions incorporating CDKL5.35
Four different duplicated regions were described,
ranging from 540 to 935 kb in size. In the case of the
683-kb duplication harbored by three of the patients,
the duplicated region does not include exon 1 of
CDKL5, so the predominant adult brain isoform,
hCDKL5_1, would not be expected to be
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overexpressed in these individuals. The authors point
out that the alternative hCDKL5_5 transcript may be
expressed and overexpression effects during fetal
development may result in the observed phenotype.
Three patients also harbored additional duplicated
regions on other chromosomes, and parents harbor-
ing these same CDKL5-containing duplications were
either phenotypically unaffected or displayed mild
intellectual disability.35 Therefore, the pathway lead-
ing to the phenotypes in these individuals remains
somewhat unclear, as experimental confirmation of
effects on CDKL5 transcript and protein levels is not
yet available. Here, we report 2 duplications and 1
triplication in our clinical cohorts (table 2). However,
in each of these copy number variations, only a part of
the gene is duplicated; therefore, it is extremely
unlikely that an increased level of CDKL5 would be
present in these individuals.
Variants in regulatory and UTRs. The recent identifica-
tion of novel exons and transcription start sites at the
59 end of the gene suggests the presence of multiple
promoter regions.12 However, most brain transcripts
are driven by a putative promoter upstream of exon 1.
Several variants in the 59-UTR have been reported,
but so far only those associated with the deletion of
exon 1 or 2, or the disruption of splicing from exon 1
to exon 2 (c.-162-2A.G36), have been shown to be
pathogenic. Only 2 variants in the putative promoter
region, c.-440G.T and c.-189C.T, have so far
been found in patients with a CDKL5-like pheno-
type,3 but at present their significance remains
uncertain. The large 6.6 kb 39-UTR of hCDKL5_1
has only recently been defined,12 so the region has not
been analyzed in patients either by targeted
sequencing or by exome analysis, and we found no
evidence for the presence of clinically relevant variants
in the 1000G data.
Incidence of CDKL5 deficiency. The incidence of
CDKL5 deficiency is unknown. We have analyzed
data from the International CDKL5 Disorder Data-
base8 to provide a lower estimate of birth prevalence
in Australia of 0.21 cases per 100,000 live births
(95% CI 0.12–0.33) for the years 1982–2014.
Although a birth prevalence in this range would indi-
cate that CDKL5 deficiency is an ultra rare disorder,
it is likely that this figure will increase, as targeted
next-generation sequencing for investigation of
early-onset epileptic encephalopathy becomes more
common.7,25
In our analysis, the most frequent CDKL5
deficiency–causing variants are 2 nonsense variants
in exon 12: c.1648C.T (p.Arg550Ter) and
c.1675C.T (p.Arg559Ter). Each of these variants
affects only 3% of all patients, highlighting the high
degree of allelic heterogeneity in CDKL5 deficiency.
DISCUSSION Large-scale sequencing studies are
powerful tools for the analysis of genetic variants in
rare diseases, such as CDKL5 deficiency. Analysis of
CDKL5 variants in this study reinforces the work of
recent studies that propose hCDKL5_1 as being the
predominant functional isoform required for normal
neurodevelopment and brain function. We have
shown that missense variants outside the catalytic
domain are unlikely to be pathogenic. We have also
highlighted specific cases that should currently be
classified as being of “uncertain significance” and have
functionally reclassified a pathogenic missense variant
as a splicing variant. Furthermore, we saw no evi-
dence that missense variants outside the catalytic
domain were overrepresented in patient populations
compared with their allele frequencies in population
databases. However, we cannot rule out the possibil-
ity that this lack of association is the result of some
missense variants having reduced penetrance and thus
existing in unaffected individuals in population co-
horts. An analysis of male and female variants sepa-
rately (in a compact subset of 15 missense variants in
the catalytic domain) was suggestive of no significant
sex differences in allele frequency (not shown). How-
ever, further analysis of all missense variants would be
recommended in a future study.
There is a lack of evidence for pathogenic variants
in exons 20, 21, and 22. Early studies of the CDKL5
gene had deemed hCDKL5_5 (formerly known as
hCDKL5115) to be the predominant CDKL5 tran-
script and protein isoform. However, we now know
that this isoform utilizing exons 20–22 is expressed
almost exclusively in the testis and found only at
extremely low levels in the adult brain.2,12,18 A recent
analysis of missense variants in these exons concluded
that genetic variation in this C-terminus was likely to
have little or no significance to a CDKL5 disorder
phenotype.37 We find further evidence of this in our
study. Furthermore, the identification of nonsense
variants in these exons in the population is an impor-
tant observation, consistent with a previous study in
which patients with a 136-kb deletion lost only these
39 CDKL5 exons and the overlapping RS1 gene.38 All
patients in the study showed only a retinoschisis
phenotype, consistent with RS1 deficiency. Together,
the data reinforces the view that variants identified at
the 39 end of the CDKL5 gene should be interpreted
with caution.
Although there is substantial evidence that
hCDKL5_1 is the predominant brain isoform,
hCDKL5_5 continues to be cited as a reference
sequence. Consequently, exon 17 and full-length
exon 19 are not always routinely sequenced in tar-
geted gene panels containing CDKL5 and are often
excluded from exome analysis (as in ExAC). This has
potentially important consequences for molecular
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diagnosis, and it is possible that pathogenic variants in
these exon regions are therefore underreported. It is
possible that the presence of isoform hCDKL5_2
(which contains exon 17) is not crucial for normal
CDKL5 function, given that the levels of this isoform
are only 10% (or less) of hCDKL5_1, at all stages of
development.12 It may be critical to analyze full-
length exon 19, as nonsense and frameshift variants
even at the 39 end of the gene are likely to be path-
ogenic. The presence of long 39-UTRs is known to be
a major factor in triggering the NMD process,27 and
the recent identification of 6.6 kb and 9.9 kb 39-
UTRs in CDKL5 brain isoforms12 suggests that
NMD could play an important role in the downre-
gulation of mRNA in the event of a premature ter-
mination codon, even in the last coding exon (exon
19 in all CDKL5 brain isoforms). Therefore, we sug-
gest that exon 17 and the full-length form of exon 19
should be included in all molecular diagnostic screens
for CDKL5 variants, whether by targeted gene panels
or by exome sequencing.
The pathogenicity of CDKL5 variants can ultimately
be tested in animal models or engineered human cell
lines.39 However, this study provides evidence for the
reclassification of specific CDKL5 variants and insights
for genetic diagnosis. Although pathogenic CDKL5 var-
iants are found across the majority of the coding regions
of the gene, missense variants clearly cluster in the N-
terminal catalytic domain. Missense variants outside this
domain and all variants in exons 20, 21, and 22 are
likely to be benign. In contrast to the well-described
duplication syndromes involving closely related genes
MECP2 and FOXG1,40,41 we believe that more evidence
is required to conclude that there is a well-defined
CDKL5 duplication syndrome. Continued evaluation
of cases investigating both genotypic and phenotypic
expressions as well as diagnoses of copy number varia-
tions involvingCDKL5may help to elucidate this aspect
of CDKL5 biology.
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